Horizon Pharma plc Form 3 November 07, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Horizon Pharma plc [HZNP] A Happel David (Month/Day/Year) 11/04/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O HORIZON PHARMA PLC, (Check all applicable) CONNAUGHT HOUSE,, 1ST FLOOR, 1 BURLINGTON 10% Owner Director **ROAD** _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group EVP Global Orphan Bus. Unit Filing(Check Applicable Line) _X_ Form filed by One Reporting Person DUBLIN, L2Â 4 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative Security 2. Date Exercisable and 4. 5. Securities Underlying **Expiration Date** Conversion Ownership Beneficial Ownership (Instr. 4) (Month/Day/Year) or Exercise Form of (Instr. 5) Derivative Security (Instr. 4) Price of Derivative Derivative Security:

Edgar Filing: Horizon Pharma plc - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	10/24/2026	Ordinary Shares	50,674	\$ 18.31	D	Â
Restricted Stock Units (RSU)	(2)	(2)	Ordinary Shares	31,813	\$ <u>(2)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
•	Director	10% Owner	Officer	Other		
Happel David C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FLOOR, 1 BURLINGTON ROAD DUBLIN, L2 4	Â	Â	EVP Global Orphan Bus. Unit	Â		

Signatures

/s/ Paul W. Hoelscher, Attorney-in-Fact

11/07/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the option vest and become exercisable on the first anniversary of the date of grant (October 25, 2016), and the remaining shares vest in 36 equal monthly installments thereafter.
- (2) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the date of grant (October 25, 2016).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2